Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

Authors

Alessandro Prestipino

Published

February 21, 2018

Abstract

Oncogenic JAK mutation sensitizes myeloproliferative neoplasms to immune checkpoint inhibition.

Supporters

Support the authors with ResearchCoin

Journal

Science Translational Medicine

Topics

DOI

10.1126/scitranslmed.aam7729

Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

Authors

Alessandro Prestipino

Published

February 21, 2018

Abstract

Oncogenic JAK mutation sensitizes myeloproliferative neoplasms to immune checkpoint inhibition.

Supporters

Support the authors with ResearchCoin

Journal

Science Translational Medicine

Topics

DOI

10.1126/scitranslmed.aam7729

Paper

Paper

Paper

Paper

Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

Abstract

Supporters

Journal

Topics

DOI

Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

Abstract

Supporters

Journal

Topics

DOI